Lung cancer is the most common cause of cancer-related-death world-wide. About 85% of lung cancers are non-small cell lung cancer (NSCLC), mostly identified after metastatic disease has evolved and are thus incurable. Significant advances have been made in recent years in the identification of driver mutations whose inhibition can prolong survival. However, metastatic spread and development of resistance to therapy inflict most patients, and five-year survival rates are around 15%. In order to improve this dismal outcome, deeper understanding into the molecular mechanisms occurs in the tumor and in its microenvironment is required and is the main goal of our research.